ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1558 • ACR Convergence 2021

    Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study

    Diana Villacis Nunez1, Kaitlin Jones2, Lucie Fan3, Whitney Moore2, Aysha Jabbar2, Matthew Oster4, Preeti Jaggi1 and Sampath Prahalad5, 1Emory University School of Medicine - Children's Healthcare of Atlanta, Atlanta, GA, 2Children's Healthcare of Atlanta, Atlanta, GA, 3Emory University School of Medicine, Atlanta, GA, 4Emory University School of Medicine - Sibley Heart Center/Children's Healthcare of Atlanta, Atlanta, GA, 5Emory + Children's Pediatric Institute, Atlanta, GA

    Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes…
  • Abstract Number: 1559 • ACR Convergence 2021

    Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India

    Arun Tiwari1, Suma Balan2, Abdul Rauf3, Mahesh kappanayil2, Sajith Kesavan2, Suchitra Sivadas2, Pranav Chickermane2, Ajay Vijayan2, Manu Raj2, Anilkumar V2 and Abish Sudhakar2, 1Amrita Institute of Medical Sciences, Ernakulam, India, 2Amrita Institute of Medical Sciences, Kochi, India, 3Baby Memorial Hospital, Kozikode, India

    Background/Purpose: COVID-19 related multisystem inflammatory syndrome in children (MIS-C) has varied clinical presentation ranging from fever with mild gastrointestinal and/or mucocutaneous changes to life threatening…
  • Abstract Number: 1560 • ACR Convergence 2021

    A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome

    Anand Kumthekar1 and Bibi Ayesha2, 1Albert Einstein College of Medicine, Bronx, NY, 2Montefiore Medical Center, Bronx, NY

    Background/Purpose: Coronavirus disease (COVID-19) patients can progress to a state of unregulated inflammation called cytokine storm syndrome (CSS). A multi-disciplinary approach is needed to identify…
  • Abstract Number: 1561 • ACR Convergence 2021

    Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic

    Jennifer Santana Peralta de Heyaime, Teresandris Polanco Mora, Angelo Cornelio Vasquez, Yamilet Cruz, Edral Rodriguez, Tirso Valdez Lorie, Roberto Munoz and Rafael Alba Feriz, Hospital Docente Padre Billini, Santo Domingo, Dominican Republic

    Background/Purpose: SARS-CoV-2 infection is caused by a new coronavirus. The World Health Organization (WHO) had information about the existence of this new virus on December…
  • Abstract Number: 1562 • ACR Convergence 2021

    B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab

    Sarah Jinich, Deanna Jannat-Khah and Robert Spiera, Hospital for Special Surgery, New York, NY

    Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…
  • Abstract Number: 1563 • ACR Convergence 2021

    Clinical Characteristics and Management of Olecranon and Prepatellar Septic Bursitis in a Multicenter Study

    Laurie Charret1, Géraldine Bart2, Emmanuel Hoppé3, Emmanuelle Dernis4, Gregoire Cormier5, David Boutoille6, Benoit Le Goff7 and Christelle Darrieutort-Laffite7, 1Rheumatology Department, CHD Vendée, La Roche-Sur-Yon, France, 2Rheumatology Department, CHU Rennes, Rennes, France, 3Rheumatology Department, CHU Angers, Angers, France, 4Rheumatology Department, CH Le Mans, Le Mans, France, 5Rheumatology Department, CHD Vendée, La Roche Sur Yon, France, 6Department of Infectious Diseases, CHU Nantes, Nantes, France, 7Rheumatology Department, CHU Nantes, Nantes, France

    Background/Purpose: Septic bursitis (SB) is a common medical problem. However, there are no current guidelines for managing the condition. The study aims to describe the…
  • Abstract Number: 1564 • ACR Convergence 2021

    Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study

    Paola Estefania Bermudez Bermejo1, RODOLFO JIMENEZ-SOTO1, Alain Sanchez-Rodríguez1, Alonso Turrent1, Daniela Mercado- Velasco1, Ian Bravo-Lee1, Mariana Berenice Colli-Cortés2, Everardo Alvarez Hernandez3 and MaryCarmen Amigo1, 1CENTRO MEDICO ABC, Mexico City, Mexico, 2Hospital Regional "General Ignacio Zaragoza" ISSSTE, Mexico City, Mexico, 3HOSPITAL GENERAL DE MEXICO, Mexico City, Mexico

    Background/Purpose: Nailfold capillaroscopy is a relatively easy-to-access, low-cost clinical tool that could help identify early coagulopathy in subjects with SARS-CoV-2, but specific findings vs. controls…
  • Abstract Number: 1565 • ACR Convergence 2021

    Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial

    Kazuki Yoshida1, Robert J. Glynn1, Hyon K. Choi2, Brendan M. Everett1, Yi Li3, Jean G. MacFadyen1, Paul M. Ridker1 and DH Solomon1, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Lexington, MA, 3Harvard T.H. Chan School of Public Health, Boston, MA

    Background/Purpose: Previous analyses in the CANTOS trial demonstrated a benefit of canakinumab (CAN; IL-1β inhibitor) on gout flares. We aimed to quantify the mediating role…
  • Abstract Number: 1566 • ACR Convergence 2021

    Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery

    Rachael Flood, Colm Kirby, David Kane and Ronan Mullan, Tallaght University Hospital, Dublin, Ireland

    Background/Purpose: Vascular endothelial cells line the entire circulatory system, these cells have very distinct and unique functions that are paramount to vascular biology. Hyperuricemia has…
  • Abstract Number: 1567 • ACR Convergence 2021

    Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients

    Luigi Brunetti1, Lujing Wang2, Andrew Wassef2, Anita Brinker3, Brian T Buckley4, Peter Lipsky5, Ah-Ng Kong2 and Naomi Schlesinger6, 1Rutgers The State University of New Jersey, Piscataway, NJ, 2Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 3Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey,, Piscataway, NJ, 4Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ, 5AMPEL BioSolutions, Charlottesville, VA, 6Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: Tart cherries (TC) contain high levels of anthocyanins that exert potent antioxidant and anti-inflammatory effects. Approximately 50% of gout patients report using TC to…
  • Abstract Number: 1568 • ACR Convergence 2021

    AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment

    zancong shen1, Elizabeth Polvent2, vijay hingorani3, Rongzi Yan4, Shunqi Yan5 and Litain Yeh6, 1Arthrosi Therapeutics, Inc., San Diego, CA, 2Arthrosi Therapeutics, Inc., Roseville, CA, 3Vanguard Healthsciences, Inc., San Diego, CA, 4Arthrosi Therapeutics, Inc, Irvine, CA, 5Arthrosi Therapeutics, Inc., Laguna Hills, CA, 6Arthrosi Therapeutics, Inc., Irvine, CA

    Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…
  • Abstract Number: 1569 • ACR Convergence 2021

    Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation

    Nicola Dalbeth1, Borislav Mihov1, Angela Stewart1, Gregory Gamble1, Tony Merriman2, David Mount3, Lisa Stamp4, Ian Reid1 and Anne Horne1, 1University of Auckland, Auckland, New Zealand, 2University of Alabama at Birmingham, Dunedin, New Zealand, 3Brigham and Women's Hospital, Boston, MA, 4University of Otago, Christchurch, Christchurch, New Zealand

    Background/Purpose: Observational studies have reported that serum urate associates with development and progression of kidney disease. However, it is uncertain whether elevated serum urate directly…
  • Abstract Number: 1570 • ACR Convergence 2021

    AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study

    Rongzi Yan1, zancong shen2, Elizabeth Polvent3, vijay hingorani4, Shunqi Yan5 and Litain Yeh6, 1Arthrosi Therapeutics, Inc, Irvine, CA, 2Arthrosi Therapeutics, Inc., San Diego, CA, 3Arthrosi Therapeutics, Inc., Roseville, CA, 4Vanguard Healthsciences, Inc., San Diego, CA, 5Arthrosi Therapeutics, Inc., Laguna Hills, CA, 6Arthrosi Therapeutics, Inc., Irvine, CA

    Background/Purpose: AR882, a novel uric acid transporter 1 (URAT1) inhibitor is being developed for the treatment of gout with hyperuricemia. In Phase 1 and Phase…
  • Abstract Number: 1571 • ACR Convergence 2021

    Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout

    Christopher Podgorski1, Paula Skarda2 and Elie Gertner3, 1Department of Medicine, University of Minnesota Medical School, Saint Paul, MN, 2Department of Medicine, Regions Hospital, University of Minnesota Medical School, Saint Paul, MN, 3Section of Rheumatology, Regions Hospital and Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN

    Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…
  • Abstract Number: 1572 • ACR Convergence 2021

    Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia

    Bilal Bengana1, Aicha Ladjouze2, Nabil Baramtane Raaf3, Chaffa Aimeur4, Soraya Ayoub5, Abdenour Boukabous6 and Salima Lefkir-Tafiani7, 1University Hospital of Beni Messous Algiers - Rheumatology Department, Algiers, Algeria, 2Specialized hospital establishment of Benaknoune, Rheumatology, Algiers, Algeria, 3Hospital of Bitraria, Biochemistry, El Biar, Algiers, Algeria, 4University hospital of Mustapha Bacha, Radiology, Sidi Mhamed, Algiers, Algeria, 5University hospital of Beni Messous, Internal Medicine, BeniMessous, Algiers, Algeria, 6University Hospital of Beni Messous Algiers- Rheumatology Department, Algiers, Algeria, 7University Hospital of Beni Messous Algiers - Rheumatology Department, Benimessous, Algeria

    Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…
  • « Previous Page
  • 1
  • …
  • 807
  • 808
  • 809
  • 810
  • 811
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology